Press Releases

JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 11/09/10 -- www.wallstreetequityresearch.com brings investors market knowledge on the aspects moving the drug related products stocks, and offers...

Fiscal first quarter revenue from continuing operations increased $113 million, or 21 percent, to a record $641 million Fiscal first quarter...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal 2011 on Tuesday, November...

Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically...

JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 09/02/10 -- www.wallstreetequityresearch.com gives shareholders valuable insight on drug related products stocks Perrigo Co. (NASDAQ: PRGO) and NBTY...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced it received FDA clearance on August 23, 2010 to manufacture infant formula liquid concentrate and ready-to-use products through its partner...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced its filing with the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for clobetasol propionate shampoo,...

-- Full-year revenue from continuing operations increased $262 million, or 13 percent, to a record $2.27 billion. -- Adjusted income from continuing operations for the full year increased 50...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on September 14, 2010 to shareholders of record...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for butoconazole nitrate vaginal...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2010 on Thursday, August 12, 2010 at approximately 8:00 a.m. (ET). The Company...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC)...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced its filing with the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Emulsion...

Perrigo (NASDAQ: PRGO)( TASE: PRGO) today announced that it has acquired the exclusive U.S. store brand rights to sell and distribute OTC versions of Fexofenadine HCl 180 mg and 60 mg tabs, plus...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging & Leisure Conference...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Executive Vice President and CFO Judy Brown will present at the 31st Annual Goldman Sachs Global Healthcare Conference on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced on May 26, 2010 that it had acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the Citi Investment Research Global Health Care Conference on Wednesday, May...

Perrigo (NASDAQ: PRGO)( TASE: PRGO) today announced that it has acquired the exclusive U.S. store brand rights to sell and distribute Dextromehtorphan Polistirex Extended Release Suspension Cough...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has closed the previously announced acquisition of PBM Holdings, Inc., the world's largest manufacturer of infant formula for...

-- Fiscal third quarter revenue from continuing operations increased $32 million, or 6%, to $538 million -- Fiscal third quarter adjusted income from continuing operations increased 49% to $70...